Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced additional interim Phase 1 clinical data for emiltatug ledadotin (Emi-Le; XMT-1660), the company's B7-H4-directed Dolasynthen ADC. These data are being presented in an oral session today at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, Illinois.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that its wholly-owned subsidiary, IQVIA Inc. (the “Issuer”), intends to raise $2,000,000,000 through an offering of senior notes due 2032 (the “Notes”). The proceeds from the Notes offering will be used to repay existing borrowings under the Issuer's revolving credit facility and to pay fees and expenses related to the Notes offering, with any excess proceeds used for other general corporate.

VALENCIA, Calif. , June 2, 2025 /PRNewswire/ -- Cunard has unveiled its latest program of extraordinary voyages with 195 new itineraries across its iconic fleet, visiting 115 destinations in 32 countries between April 2027 and January 2028.

Alpine Income Property Trust gets a buy rating for my initial coverage, as I continue my look into various types of REITs. Notables include high occupancy levels, portfolio growth and national diversification, and a tenant roster of top-tier retail names like Dick's and Walmart. Besides a solid EBITDA margin within its sector, and proven 5-year dividend growth, operating cashflow also has been positive.

ATLANTA--(BUSINESS WIRE)--Guardian Pharmacy Services, Inc. (NYSE: GRDN) announced its acquisition of Mercury Pharmacy Services in Mountlake Terrace, Washington.

During every Coach's Challenge, Chipotle will challenge fans to find a hidden keyword in a post on X for the chance to win a free entree* In response to basketball fans' frustration with lengthy replay reviews, "Chipotle Instant Freeplays" keeps the momentum going even when the game comes to a halt NEWPORT BEACH, Calif. , June 2, 2025 /PRNewswire/ -- Chipotle Mexican Grill (NYSE: CMG) today announced a new promotion called "Chipotle Instant Freeplays" ahead of the 2025 men's professional basketball championship series.

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Ameresco, Inc., (NYSE: AMRC), a leading energy solutions provider dedicated to helping customers navigate the energy transition today announced the successful sale of approximately $71 million in Investment Tax Credits (ITCs) generated from three of its landfill-gas-to-renewable natural gas (RNG) projects. These projects, which Ameresco developed, constructed, financed, and currently operates, were placed in service in 2024. This transaction marks Ameresco's.

Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology

With Expected Second Quarter 2025 closing, Core Gaming Timing Now at a Crossroads Denver, Colorado--(Newsfile Corp. - June 2, 2025) - 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and information, provides a critical update on Siyata Mobile's (NASDAQ: SYTA) $160 million merger with Core Gaming, though a precise closing date remains under wraps. Please click here for Core Gaming Merger Notes and Analysis, or insights from the ValueScope Report.

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the National Comprehensive Cancer Network (NCCN) has included the Shield blood test in its updated colorectal cancer (CRC) screening guidelines. The Shield test detects CRC signals in the bloodstream from DNA that is shed by tumors, called circulating tumor DNA (ctDNA). The updated NCCN CRC Screening Guidelines reflect the addition of Shield with a recommendation fo.

Breakthrough Second-Line Treatment Demonstrated Survival Advantage over Standard-of-Care Chemotherapy Late-Breaking Data Presented at ASCO 2025 and Simultaneously Published in The New England Journal of Medicine THOUSAND OAKS, Calif. , June 2, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA® (tarlatamab-dlle) reduced the risk of death by 40% and significantly extended median overall survival (OS) by more than five months compared to standard-of-care (SOC) chemotherapy in patients with small cell lung cancer (SCLC) who progressed on or after one line of platinum-based chemotherapy (median OS: 13.6 vs 8.3 months; hazard …

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients with advanced or metastatic Merkel cell carcinoma (MCC) detailed in Trial in Progress Poster at ASCO Phase 3 trial of IFx-Hu2.0 to be conducted under Accelerated Approval Pathway and Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) TAMPA, Fla. , June 2, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that Moffitt Cancer Center presented a Trial in Progress poster of the Company's planned …

Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career

Company Announcement COPENHAGEN, Denmark; June 2, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease had worsened after an initial round of chemo, according to interim data from a late-stage trial presented at a major medical meeting on Monday.

PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients

NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE) (“Lineage” or the “Company”), the world's largest global temperature-controlled warehouse REIT, has issued a business update ahead of its fireside chat at Nareit's REITweek 2025 Investor Conference, scheduled for Tuesday, June 3, 2025, at 11:45 a.m. E.T. In the business update, which is available at ir.onelineage.com/events-and-presentations, Lineage is reaffirming its 2025 guidance and announcing that its second quarter to date is in l.

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

Jeff Hirsch, Starz president and CEO, joins 'Squawk Box' to discuss the separation from Lionsgate, content spending, state of the media landscape, subscriber growth, and more.